Primary end points

This site is intended only for healthcare professionals in UAE, Kuwait, Qatar, Bahrain, Oman.

Sign In or Register

Log Out

Our Medicines

Therapy Areas

Explore Content

Events

Downloadable Materials

Videos

Let's Connect

Pfizer medical information

Adverse event reporting can be found at the bottom of the page

Efficacy

PALOMA-2

Study design

Patient Characteristics

Primary endpoint

Secondary end point

PALOMA-3

Study design

Patient Characteristics

Primary endpoint

Secondary end point

Survival

Final analysis

Subgroup analysis

Prespecified groups

Updated Subgroup analysis

Safety

PALOMA pooled analysis Adverse reactions & Laboratory abnormalities

PALOMA 2 Adverse Events

PALOMA 3 Adverse Events

IBRANCE consistent safety profile

Pooled analysis of patients aged ≥65 years in the PALOMA trials

No evidence of cumulative or delayed toxicity with up to 50 months

Patients with visceral diseases

GI , Liver toxicities, and QTC

Dosing

Once daily dosing

Dose Modification

Real-World Evidence

IBRANCE is the only CDK4/6 inhibitor with >5 years of real-world experience

Real-world data provide additional information

Favorable progression free rates

IRIS Study

In the real world, IBRANCE benefits

Guidelines

NCCN Guidelines

ESMO Guidelines

Resources

Events

Materials

Videos

Information on how to access Ibrance® (palbociclib) prescribing information and adverse event reporting can be found at the bottom of the page.

Adapted from Cristofanilli M, et al. 20161; Ibrance LPD. ²
*Evaluated according to RECIST Version 1.1^.1
^†Data cut-off date: 16 March 2015.
^‡Updated non-prespecified analysis. Data cut-off date: 23 October 2015.
CI = confidence interval; ET = endocrine therapy; FUL = fulvestrant; HER2- = human epidermal growth factor receptor 2-negative; HR+= hormone receptor-positive; HR = hazard ratio; mBC = metastatic breast cancer; mPFS = median progression-free survival; PALOMA-3: the Palbociclib ongoing trials in the management of breast cancer 3 PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumours; LPD= Local Product Document.

References: 1. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439. 2. Ibrance^® (palbociclib) Local Product Document. Revision Date: September 2023 for UAE, Bahrain, Kuwait, Oman & Qatar.

Improved tumour response with IBRANCE + fulvestrant versus placebo + fulvestrant in first-line or later treatment (secondary end point)¹

Adapted from Ibrance LPD.¹
Data cut-off date: 23 October 2015.
*Defined as confirmed CR or PR.²
FUL = fulvestrant; ITT = intention-to-treat; ORR = objective response rate; PR= partial response; PLA = placebo; SR= stable disease.
References:
1. Ibrance® (palbociclib) Local Product Document. Revision Date: September 2023 for UAE, Bahrain, Kuwait, Oman & Qatar.
2. Turner NC, et al. Ann Oncol. 2018;29(3):669-680.

Report Adverse Events

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro account

PfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign In or Register

Account

Sign Out

i- The product information provided in this site is intended only for Healthcare Professionals of UAE, Kuwait, Qatar, Bahrain, Oman.

ii- The information contained on this website is offered for educational purposes only and does not represent medical advice, diagnosis, treatment or a professional recommendation. Pfizer will not be responsible for the use or interpretation of the information by the user of the website.

iii- The products discussed herein may have a different product labeling than authorized in your country and may not be available in some territories.

PP-UNP-BHR-0298